Clinical trials: Therapy Effect
Glioma, Astrocytoma
The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
The purpose of this non-randomized, open-label, multicenter, Phase II, 2-stage design, RESCUE study is to test the hypothesis that continuous 28-day oral dosing (28/28) with dose-intense temozolomide (50 mg/m^2) for up to 12…
- Conditions
- Glioma, Astrocytoma, Oligodendroglioma, Glioblastoma
- Trial name
- NCT00392171
- Testing
- Temozolomide
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Anal Fissure
An Open Label Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing in Human Subjects
This is an open label study. The study will consist of 1 treatment group: coated Nifedipine suppository containing 12 mg of Nifedipine, administered BID to subjects with chronic anal fissure.
- Trial name
- NCT00972907
- Testing
- Nifedipine coated suppositories
- Where
- 2 sites in Israel
- Volunteers
- 20 people
- Sponsor
- RDD Pharma Ltd
Diabetes Mellitus Type 2
A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.
This 3-arm study will assess the efficacy, safety and tolerability of taspoglutide compared to insulin glargine in patients with insulin-naive type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea…
- Trial name
- NCT00755287
- Testing
- insulin glargine, metformin, taspoglutide
- Where
- 210 sites in United States, Australia and 25 more
- Volunteers
- 1,072 people
- Sponsor
- Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease
Functional Respiratory Imaging Study (FRI)
The purpose of this study is to evaluate the effect of inhaled extrafine CHF5993 pMDI on airway volumes, and resistance, by Functional Respiratory Imaging (FRI), in COPD patients
- Trial name
- FRI (NCT03268226)
- Testing
- Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
- Where
- 5 sites in Belgium, Hungary
- Volunteers
- 20 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Soil-transmitted Helminth Infection, Onchocerciasis (River Blindness)
A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants
Onchocerciasis or river blindness is an infectious disease caused by a parasitic worm. It spreads through the bite of an infected blackfly.
- Trial name
- NCT06412926
- Testing
- BAY 44-4400
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Effects of Different Meals on the QT/QTc Interval, Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use
Food and Insulin Effect on QT/QTC Interval of ECG
Moxifloxacin is routinely used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. It has been shown that a meal shortens the QT interval, which may affect pharmacokinetics (PK) and/or…
- Conditions
- Effects of Different Meals on the QT/QTc Interval, Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use, C-Peptide Effects on the QT/QTc Interval, Moxifloxacin ECG Profile in Fed and Fasted State
- Trial name
- C11035 (NCT01642485)
- Testing
- Moxifloxacin 400 mg fasted, FDA breakfast, Continental breakfast
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Richmond Pharmacology Limited
Parkinson Disease
Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease
Study to measure the continued effectiveness of apomorphine after previous exposure of at least three months duration.
- Trial name
- NCT00200525
- Testing
- apomorphine HCl injection
- Volunteers
- 60 people
- Sponsor
- Mylan Bertek Pharmaceuticals
Healthy Subjects
Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects
This study will evaluate the effect of CYP3A weak inducer rufinamide on the pharmacokinetics (PK) of Quizartinib in healthy subjects
- Trial name
- NCT06740825
- Testing
- Quizartinib, Rufinamide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Ovarian Neoplasms, Ascites
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer. Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)…
- Trial name
- NCT00327444
- Testing
- aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- Where
- 9 sites in United States, Austria and 7 more
- Volunteers
- 58 people
- Sponsor
- Sanofi
Obesity
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with…
- Trial name
- GZBF (NCT07467447)
- Testing
- Retatrutide (LY3437943), Standardized diet and physical activity counseling throughout the study.
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Hudson Biotech
Satiety of High Fiber High Protein Bread
Effect of EverVita Pro, a Protein Rich Ingredient, on Satiety Measures, Subsequent Energy Intake, and Gastrointestinal Symptoms: A Randomized, Controlled, Cross-over Study in Healthy Subjects
This study will explore the satiating effect of EverVita Pro when consumed at breakfast on subsequent food intake. On 2 separate days, subjects will consume in random order a test breakfast (bread, butter, jam), either containing…
- Trial name
- NCT04869215
- Testing
- EverVita Pro, Control bread
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Evergrain, LLC
Medial Compartment Knee Osteoarthritis
The Effect of a Novel Joint Distraction Knee Orthosis for Treating Medial Knee Osteoarthritis
The Effect of a Novel Joint Distraction Knee Orthosis for Treating Medial Knee Osteoarthritis
- Trial name
- NCT07439315
- Testing
- Medial joint distraction brace
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Icarus Medical Innovations
Overweight, Obesity Grade I
Clinical Trial to Evaluate the Effect of a Probiotic Product on Weight
The study of the intestinal microbiota and its relationship with health and disease, as well as the use of probiotics as effective alternative treatments to improve people's well-being is a field of growing research in recent…
- Trial name
- NCT06815926
- Testing
- Probiotic
- Where
- Spain
- Volunteers
- 106 people
- Sponsor
- Bioithas SL
Healthy
Effect of Rifampin on Bosutinib When Both Are Given to Healthy People
Study to examine whether rifampin has an effect on the pharmacokinetics of bosutinib.
- Trial name
- NCT00725426
- Testing
- Bosutinib
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Type 2 Diabetes Mellitus
A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics
This study is intended to evaluate the pharmacodynamics, safety, and tolerability of LX4211 when administered concurrently with sitagliptin (Januvia®) in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01441232
- Testing
- LX4211, Januvia®
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Lexicon Pharmaceuticals
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with…
- Trial name
- BE UNIQUE (NCT06506916)
- Testing
- bimekizumab
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3
Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)
This study is designed to establish the effect of 2 doses of vonafexor on the kidney. This will be investigated in subjects with mild or moderate reduced estimated glomerular filtration rate (eGFR) and suspected MASH.
- Conditions
- Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Metabolic Dysfunction-Associated Steatohepatitis
- Trial name
- MASH (NCT06939816)
- Testing
- Vonafexor low dose, Vonafexor high dose
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Enyo Pharma
Infant Nutrition
Effect of Formula on Growth of Infants From Overweight or Obese Mothers
The purpose of this study is to determine whether infants, from overweight or obese mothers, fed a formula with proteins and calories different than a standard infant formula have a different growth
- Trial name
- NCT00820833
- Testing
- standard infant formula, Test formula
- Where
- Chile
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Vulvovaginal Candidiasis, Genital
Effect of Ultra-gyn® on Vulvovaginal Candidiasis
The aim of this post-market clinical follow up study is to confirm the performance and the safety of Ultra-gyn® (when used in accordance with its approved labelling)
- Trial name
- NCT05273333
- Testing
- Ultra-gyn®
- Where
- Mauritius
- Volunteers
- 30 people
- Sponsor
- Biocodex
HIV Infections
Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy
The purpose of this study is to see if it is safe and effective to give HIV-positive patients L2-7001 (a type of interleukin-2) plus anti-HIV therapy.
- Trial name
- NCT00002449
- Testing
- Aldesleukin
- Where
- 23 sites in United States
- Volunteers
- 212 people
- Sponsor
- Chiron Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.